Autres langues MediWound Ltd.

Actions

MDWD

IL0011316309

Temps réel estimé Cboe BZX Autres places de cotation 17:42:29 26/04/2024			Varia. 5j.	Varia. 1 janv.
18,34 ^USD	+3,88 %		+16,49 %	+80,63 %

21/03	MediWound Ltd. fournit des prévisions de revenus pour les années 2025 et 2026	CI
21/03	Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	25/04
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	25/04
MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	21/03
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M	21/03
MediWound: Q4 Earnings Snapshot	21/03
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	21/03
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	14/03
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	14/03
Sector Update: Health Care Stocks Mixed Late Afternoon	12/02
MediWound Shares Rise After Positive Results From EscharEx Comparison Study	12/02
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study	12/02
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study	12/02
MediWound to Participate in Two Upcoming Investor Conferences	05/02
MediWound to Participate in Two Upcoming Investor Conferences	05/02
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA	09/01
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	09/01
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	09/01
Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns	09/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues MediWound Ltd.

Actions

MDWD

IL0011316309

Autres langues

Filtres